retatrutide type 2 diabetes trial nct Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Delivers Significant Hemoglobin A1C

doi: 10.1001/jama.2023.19897.2812316 [DOI] [PMC free article] [PubMed] [Google Scholar] 2.Felisbino-Mendes MS, Cousin E, Malta DC, Machado IE, Ribeiro ALP, Duncan BB, Schmidt MI, Silva DAS, Glenn S, Afshin A, Velasquez-Melendez G

Wegovy generated revenues of $913 million in 2022 and $673.7 million in the first quarter of 2023

Fatty liver disease (NAFLD or MASH)

That has me like the Animaniacs, yelling HELLOOOOOO NURSE! The Research: GLP-1 and Addiction So, what does the science actually say

Enter novel therapeutics like CCT217: By driving beige fat activation and functional thermogenesis, these agents could rapidly improve insulin sensitivity, ApoB/TG, hsCRP, hepatic fat, and microvascular functioneven before the scale moves

Future Outlook Older patients with skin laxity following weight loss are often marinating in real world solutions